Advanced search
Publication Cover
Expert Review of Hematology Volume 14, 2021 - Issue 9
Submit an article Journal homepage
2,232
Views
5
CrossRef citations to date
0
Altmetric
Original research

Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma

Yuqin Songa Department of Clinical Oncology, Beijing Cancer Hospital, Beijing, ChinaView further author information
,
Ye Guob Department of Oncology, Shanghai East Hospital, Tongji University, Shanghai, ChinaView further author information
,
Huiqiang Huangc Department of Medicine, Sun-Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Wei Lid Department of Oncology, The First Hospital of Jilin University, Changchun City, ChinaView further author information
,
Xiaoyan Kee Department of Hematology, Peking University Third Hospital, Beijing, ChinaView further author information
,
Jifeng Fengf Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, ChinaView further author information
,
Wei Xug Department of Hematology, Jiangsu Province People’s Hospital, Nanjing, ChinaView further author information
,
Harry Miaoh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Judith Kinleyh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Gregory Songh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Yi Daih Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
,
Hui Wangh Department of Clinical Oncology, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USAView further author information
&
Jun Zhui Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 867-875 | Received 08 Apr 2021, Accepted 10 Jun 2021, Published online: 24 Aug 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Burhan Ferhanoglu & Murat Ozbalak. (2023) Sequencing novel agents in the treatment of classical Hodgkin lymphoma. Expert Review of Hematology 0:0, pages 1-25.
Read now

Articles from other publishers (4)

Marouane Maaroufi. (2023) Immunotherapy for Hodgkin lymphoma: From monoclonal antibodies to chimeric antigen receptor T-cell therapy. Critical Reviews in Oncology/Hematology 182, pages 103923.
Crossref
Daniela Verzella, Jessica Cornice, Paola Arboretto, Davide Vecchiotti, Mauro Di Vito Nolfi, Daria Capece, Francesca Zazzeroni & Guido Franzoso. (2022) The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target. Biomedicines 10:9, pages 2233.
Crossref
Kebing Lv, Ting Yin, Min Yu, Zhiwei Chen, Yulan Zhou & Fei Li. (2022) Treatment Advances in EBV Related Lymphoproliferative Diseases. Frontiers in Oncology 12.
Crossref
Roser Velasco, Eva Domingo-Domenech & Anna Sureda. (2021) Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy. Cancers 13:23, pages 6125.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.